Decongestant sprays (oxymetazoline, phenylephrine) work in minutes — they shrink swollen blood vessels in the nose. Steroid sprays (fluticasone, mometasone) take days but reduce inflammation for weeks. The nasal spray market report by MRFR shows that decongestion sprays are the largest segment, but steroid sprays are the fastest‑growing. The market is $28.94 billion and will hit $62.2 billion by 2035, growing at 7.2% CAGR. Why the shift? Because patients are learning that steroids treat the cause, not just the symptom.

What's driving growth? Over‑the‑counter (OTC) sprays are the largest category, but prescription sprays are the fastest‑growing — for chronic conditions like allergic rhinitis and nasal polyps. The nasal spray market analysis highlights that pump bottles are the largest container design, but pressurized canisters are growing fast — they deliver a consistent dose and don't require priming.

What's new? Nasal sprays for migraine (zolmitriptan) and even for COVID‑19 vaccines (intranasal) are in development. The nose is a great route to the brain and the immune system.

The bottom line: if you have occasional congestion, decongestant spray is fine. If you have chronic allergies, switch to a steroid spray. It takes longer, but it works better.